Amstrin Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.50 Cr
as on 11-12-2024
- Paid Up Capital ₹ 6.25 M
as on 11-12-2024
- Company Age 37 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 2.10 Cr
as on 11-12-2024
- Revenue 10.60%
(FY 2023)
- Profit -2.32%
(FY 2023)
- Ebitda -46.31%
(FY 2023)
- Net Worth 6.42%
(FY 2023)
- Total Assets -7.68%
(FY 2023)
About Amstrin Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.50 Cr and a paid-up capital of Rs 6.25 M.
The company has closed loans amounting to ₹2.10 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Girish Shah and Raj Shah serve as directors at the Company.
- CIN/LLPIN
U24239MH1987PTC043234
- Company No.
043234
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 Apr 1987
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Amstrin Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Girish Shah  | Director | 09-Jun-2009 | Current |
| Raj Shah | Director | 03-Aug-2019 | Current |
Financial Performance of Amstrin Pharma.
Amstrin Pharma Pvt Ltd, for the financial year ended 2023, experienced significant growth in revenue, with a 10.6% increase. The company also saw a slight decrease in profitability, with a 2.32% decrease in profit. The company's net worth moved up by a moderate rise of 6.42%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Amstrin Pharma?
In 2023, Amstrin Pharma had a public holding of 4.41%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Phalashruti Shikshan Mandal Private LimitedActive 30 years 5 monthsGirish Shah and Raj Shah are mutual person
Printography Systems (India ) Private LimitedActive 19 years 10 monthsGirish Shah and Raj Shah are mutual person
- Printguard Security Press Private LimitedActive 18 years 3 months
Girish Shah and Raj Shah are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 12 Apr 1998 | ₹7.62 M | Satisfied |
State Bank Of India Creation Date: 29 Jul 1997 | ₹5.00 M | Satisfied |
State Bank Of India Creation Date: 13 May 1995 | ₹2.50 M | Satisfied |
How Many Employees Work at Amstrin Pharma?
Unlock and access historical data on people associated with Amstrin Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Amstrin Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Amstrin Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
